Alise Reicin is the Chief Executive Officer at Tectonic Therapeutic, and brings extensive early and late stage clinical drug development experience leading to the approval of over 10 novel therapies across a broad range of therapeutic areas. Previously, she served as President, Global Clinical Development for Celgene and prior to this she was Head of Global Clinical Development for EMD Serono. Dr. Reicin had a 19 year career at Merck in which she had leadership roles across a wide variety of therapeutic areas. In her capacity as Vice President, Oncology, she led the Keytruda program and oversaw the initial development and filing activities worldwide, and the initiation of development plans in seven different indications. Prior to Merck, Dr. Reicin was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital.